1. Home
  2. PZG vs KLRS Comparison

PZG vs KLRS Comparison

Compare PZG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.55

Market Cap

140.0M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

116.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
KLRS
Founded
1992
2019
Country
United States
United States
Employees
N/A
20
Industry
Metal Mining
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.0M
116.8M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PZG
KLRS
Price
$1.55
$4.72
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
591.7K
85.6K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$330,259.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$2.14
52 Week High
$2.70
$11.88

Technical Indicators

Market Signals
Indicator
PZG
KLRS
Relative Strength Index (RSI) 47.21 29.81
Support Level $1.50 $4.35
Resistance Level $1.88 $5.38
Average True Range (ATR) 0.09 0.31
MACD 0.01 -0.04
Stochastic Oscillator 59.30 6.22

Price Performance

Historical Comparison
PZG
KLRS

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: